View Item 

Show simple item record

A risk score to predict the development of hepatic encephalopathy in a populationâ based cohort of patients with cirrhosis
dc.contributor.authorTapper, Elliot B.
dc.contributor.authorParikh, Neehar D.
dc.contributor.authorSengupta, Neil
dc.contributor.authorMellinger, Jessica
dc.contributor.authorRatz, David
dc.contributor.authorLok, Anna S.‐f.
dc.contributor.authorSu, Grace L.
dc.date.accessioned2018-11-20T15:35:00Z
dc.date.available2019-12-02T14:55:09Zen
dc.date.issued2018-10
dc.identifier.citationTapper, Elliot B.; Parikh, Neehar D.; Sengupta, Neil; Mellinger, Jessica; Ratz, David; Lok, Anna S.‐f. ; Su, Grace L. (2018). "A risk score to predict the development of hepatic encephalopathy in a populationâ based cohort of patients with cirrhosis." Hepatology 68(4): 1498-1507.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/146442
dc.publisherWiley Periodicals, Inc.
dc.publisherFood and Drug Administration
dc.titleA risk score to predict the development of hepatic encephalopathy in a populationâ based cohort of patients with cirrhosis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/1/hep29628_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/2/hep29628-sup-0001-suppinfo.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/3/hep29628.pdf
dc.identifier.doi10.1002/hep.29628
dc.identifier.sourceHepatology
dc.identifier.citedreferenceMarrone G, Maesoâ Díaz R, Garcíaâ Cardena G, Abraldes JG, Garcíaâ Pagán JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 2015; 64: 1434 â 1443.
dc.identifier.citedreferenceAmpuero J, Ranchal I, Nunez D, del Mar Díazâ Herrero M, Maraver M, del Campo JA, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 2012; 7: e49279.
dc.identifier.citedreferenceBajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garciaâ Tsao G, et al. The 3â month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016; 64: 200 â 208.
dc.identifier.citedreferenceSteyerberg EW, Harrell FE, Borsboom GJ, Eijkemans M, Vergouwe Y, Habbema JDF. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774 â 781.
dc.identifier.citedreferenceSullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23: 1631 â 1660.
dc.identifier.citedreferenceSengupta N, Tapper EB. Derivation and internal validation of a clinical prediction tool for 30â day mortality in lower gastrointestinal bleeding. Am J Med 2017; 130: 601.
dc.identifier.citedreferenceAbraldes JG, Albillos A, Bañares R, Turnes J, González R, Garcíaâ Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651 â 1658.
dc.identifier.citedreferenceHuang Yâ W, Lee Câ L, Yang Sâ S, Fu Sâ C, Chen Yâ Y, Wang Tâ C, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol 2016; 111: 976 â 985.
dc.identifier.citedreferenceAbraldes JG, Villanueva C, Aracil C, Turnes J, Hernandezâ Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150: 1160 â 1170.
dc.identifier.citedreferenceMohanty A, Tate JP, Garciaâ Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis Câ related compensated cirrhosis. Gastroenterology 2016; 150: 430 â 440.
dc.identifier.citedreferenceGines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122 â 128.
dc.identifier.citedreferenceTapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiologyâ driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc 2015; 90: 646 â 658.
dc.identifier.citedreferenceVilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60: 715 â 735.
dc.identifier.citedreferenceBajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. Hepatology 2007; 45: 833 â 834.
dc.identifier.citedreferencePatel AV, Wade JB, Thacker LR, Sterling RK, Siddiqui MS, Stravitz RT, et al. Cognitive reserve is a determinant of healthâ related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for endâ stage liver disease score. Clin Gastroenterol Hepatol 2015; 13: 987 â 991.
dc.identifier.citedreferenceSangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17â year cohort study of 214 patients. Hepatology 2006; 43: 1303 â 1310.
dc.identifier.citedreferenceGomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, et al. The natural history of compensated HCVâ related cirrhosis: a prospective longâ term study. J Hepatol 2013; 58: 434 â 444.
dc.identifier.citedreferenceDienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396 â 405.
dc.identifier.citedreferenceKonerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology 2015; 61: 1832 â 1841.
dc.identifier.citedreferenceTapper EB, Hughes MS, Buti M, Dufour Jâ F, Flamm S, Firdoos S, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C cirrhosis: a costâ effectiveness analysis. Transplantation 2017; 101: 987 â 995.
dc.identifier.citedreferenceLackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine longâ term prognosis in patients with alcoholic liver disease. J Hepatol 2017; 66: 610 â 618.
dc.identifier.citedreferenceSchuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838 â 851.
dc.identifier.citedreferenceD’Amico G, Garciaâ Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217 â 231.
dc.identifier.citedreferenceWong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl 2014; 20: 1454 â 1461.
dc.identifier.citedreferenceTapper EB, Risechâ Neyman Y, Sengupta N. Psychoactive medications increase the risk of falls and fallâ related injuries in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 1670 â 1675.
dc.identifier.citedreferenceBajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1591 â 1600.
dc.identifier.citedreferenceBajaj JS, Hafeezullah M, Hoffmann RG, Varma RR, Franco J, Binion DG, et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008; 47: 596 â 604.
dc.identifier.citedreferenceTapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Chang M, Lai M. A quality improvement initiative reduces 30â day rate of readmission for patients with cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 753 â 759.
dc.identifier.citedreferenceTapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate populationâ based cohort study. Clin Gastroenterol Hepatol 2016; 14: 1181 â 1188.
dc.identifier.citedreferenceJepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish populationâ based cohort study. Hepatology 2010; 51: 1675 â 1682.
dc.identifier.citedreferenceFDAâ NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD: Food and Drug Administration; Bethesda, MD: National Institutes of Health; 2016.
dc.identifier.citedreferenceMoons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015; 162: W1 â W73.
dc.identifier.citedreferenceKanwal F, Kramer JR, Buchanan P, Asch SM, Assioun Y, Bacon BR, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology 2012; 143: 70 â 77.
dc.identifier.citedreferenceNehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 2013; 47: e50.
dc.identifier.citedreferenceGoldberg D, Lewis J, Halpern S, Weiner M, Lo Re V. Validation of three coding algorithms to identify patients with endâ stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 2012; 21: 765 â 769.
dc.identifier.citedreferenceWest AN, Lee RE, Shambaughâ Miller MD, Bair BD, Mueller KJ, Lilly RS, et al. Defining â ruralâ for veterans’ health care planning. J Rural Health 2010; 26: 301 â 309.
dc.identifier.citedreferenceBush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDITâ C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789 â 1795.
dc.identifier.citedreferenceElixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical Care 1998; 36: 8 â 27.
dc.identifier.citedreferenceKamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with endâ stage liver disease. Hepatology 2001; 33: 464 â 470.
dc.identifier.citedreferenceKim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and metaâ analysis. Clin Gastroenterol Hepatol 2017; 15: 1521 â 1530.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep29628_am.pdf
Size:
783.8KB
Format:
PDF
View/Open
Name:
hep29628-sup-0001-suppinfo.pdf
Size:
176.8KB
Format:
PDF
View/Open
Name:
hep29628.pdf
Size:
457.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.